- Journal club critique
- Open Access
Comparing different thrombolytic dosing regimens for treatment of acute pulmonary embolism
© BioMed Central Ltd 2010
- Published: 15 October 2010
Ch en Wang, Zh enguo Zhai, Yuanhua Yang, Qi Wu, Zhaozhong Cheng, Lirong Liang, Huaping Dai, Kewu Huang, Weixuan Lu, Zhonghe Zhang, Xiansheng Cheng, Ying H Shen, For the China Venous Thromboembolism (VTE) Study Group: Chest 2010, 137:254-262. Trial registration: clinicaltrials.gov; Identifier: NCT00781378.
Optimal dosing of recombinant tissue-type plasminogen activator (rt-PA) is important in treating pulmonary thromboembolism (PTE).
The aim of this study was to compare the efficacy and safety of a 50 mg/2 h rt-PA regimen with a 100 mg/2 h rt-PA regimen in patients with acute PTE.
A prospective, randomized, open label trial.
A multicenter trial in China.
118 patients with acute PTE and either hemodynamic instability or massive pulmonary artery obstruction.
Patients were randomly assigned to receive a treatment regimen of either rt-PA at 50 mg/2 h (n = 65) or 100 mg/2 h (n = 53).
The efficacy was determined by observing the improvements of right ventricular dysfunctions (RVDs) on echocardiograms, lung perfusion defects on ventilation perfusion lung scans, and pulmonary artery obstructions on CT angiograms. The adverse events, including death, bleeding, and PTE recurrence, was also evaluated.
Progressive improvements in RVDs, lung perfusion defects, and pulmonary artery obstructions were found to be similar in both treatment groups. This is true for patients with either hemodynamic instability or massive pulmonary artery obstruction. Three (6%) patients in the rt-PA 100 mg/2 h group and one (2%) in the rt-PA 50 mg/2 h group died as the result of either PTE or bleeding. Importantly, the 50 mg/2 h rt-PA regimen resulted in less bleeding tendency than the 100 mg/2 h regimen (3% vs. 10%), especially in patients with a body weight, 65 kg (14.8% vs. 41.2%, P = 0.049). No fatal recurrent PTE was found in either group.
Compared with the 100 mg/2 h regimen, the 50 mg/2 h rt-PA regimen exhibits similar efficacy and perhaps better safety in patients with acute PTE. These findings support the notion that optimizing rt-PA dosing is worthwhile when treating patients with PTE.
- Capstick T, Henry MT: Efficacy of thrombolytic agents in the treatment of pulmonary embolism. Eur Respir J. 2005, 26: 864-874. 10.1183/09031936.05.00002505.View ArticlePubMedGoogle Scholar
- Agnelli G, Becattini C, Kirschstein T: Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med. 2002, 162: 2537-2541. 10.1001/archinte.162.22.2537.View ArticlePubMedGoogle Scholar
- Wan S, Quinlan DJ, Agnelli G, Eikelboom JW: Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004, 110: 744-749. 10.1161/01.CIR.0000137826.09715.9C.View ArticlePubMedGoogle Scholar
- Fiumara K, Kucher N, Fanikos J, Goldhaber SZ: Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol. 2006, 97: 127-129. 10.1016/j.amjcard.2005.07.117.View ArticlePubMedGoogle Scholar
- Goldhaber SZ, Agnelli G, Levine MN: Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest. 1994, 106: 718-724. 10.1378/chest.106.3.718.View ArticlePubMedGoogle Scholar
- Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M: A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990, 98: 1473-1479. 10.1378/chest.98.6.1473.View ArticlePubMedGoogle Scholar
- Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, Dai H, Huang K, Lu W, Zhang Z, Cheng X, Shen YH: Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010, 137: 254-262. 10.1378/chest.09-0765.View ArticlePubMedGoogle Scholar